Valneva Reports H1 2026 Product Sales Of €64.0M Down From €91.0M YoY, Net Loss Widens To €63.3M From €20.8M YoY
- Total product sales of €64.0 million
- In-line with expectations; full-year guidance of €135 -150 million reaffirmed
- Solid cash position of €121.5 million as of end June 2026
- Reflects disciplined cash management and proceeds from the recent reserved offering1
- Restructuring program implemented with positive P&L and cash flow impacts expected in the second half of the year and beyond
- Regulatory decisions for Lyme disease vaccine candidate expected in the next twelve months2
- Pfizer remains optimistic about obtaining registration for the vaccine candidate3
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。